Fig. 1

Study flow chart. Among the 78 patients who received their first administration of lenvatinib between May 2018 and December 2023, 67 were selected for analysis after excluding those treated on an outpatient basis, those who received oral administration for less than 7 days, and those with Grade 3 hypertension (≥160/100 mmHg) at the initiation of treatment. The group with a median increase in systolic blood pressure (SBP) of 26 mmHg or more, calculated as the highest systolic blood pressure during the hospitalization minus the systolic blood pressure on admission, was defined as the blood pressure elevation group. This group was compared with the blood pressure non-elevation group, which had an increase in SBP of less than 26 mmHg, in terms of patient background and prognosis